# Nuclide record neuroblastoma (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/neuroblastoma/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "neuroblastoma" ;
  schema:name "Neuroblastoma (paediatric)"@en ;
  schema:description "Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."@en ;
  schema:url <https://nuclide.cc/indications/neuroblastoma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q938205> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  nuclide:tag "paediatric", "spike" ;
  nuclide:related <https://nuclide.cc/isotopes/i-131/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/mibg-theranostics/> ;
  nuclide:companies <https://nuclide.cc/companies/y-mabs/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mskcc/>, <https://nuclide.cc/institutions/dana-farber/> ;
  nuclide:trials <https://nuclide.cc/trials/nct04724369/> ;
  nuclide:pipeline <https://nuclide.cc/trials/anbl1531/>, <https://nuclide.cc/drugs/i131-mibg/>, <https://nuclide.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://nuclide.cc/technologies/mibg-theranostics/>, <https://nuclide.cc/companies/y-mabs/> ;
  nuclide:standardOfCare <https://nuclide.cc/trials/anbl1531/>, <https://nuclide.cc/drugs/i131-mibg/>, <https://nuclide.cc/drugs/i131-mibg/> .